Avanos Medical, Inc. (AVNS)
USD 16.18
(-4.94%)
USD 16.18
(-4.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 53.2 Million USD | -19.85% |
| 2022 | 77.8 Million USD | 159.28% |
| 2021 | 8.9 Million USD | 2470.0% |
| 2020 | -2 Million USD | 83.47% |
| 2019 | -12.1 Million USD | -128.95% |
| 2018 | 65.7 Million USD | 121.16% |
| 2017 | -600 Thousand USD | -87.66% |
| 2016 | -65.5 Million USD | -5.43% |
| 2015 | -76.5 Million USD | -11.28% |
| 2014 | 179.7 Million USD | -38.54% |
| 2013 | 297.1 Million USD | 3.09% |
| 2012 | 288.2 Million USD | 8.39% |
| 2011 | 265.9 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 27.4 Million USD | 21.69% |
| 2024 Q3 | 24.4 Million USD | 6.09% |
| 2024 Q1 | 18.8 Million USD | -37.62% |
| 2023 Q3 | 13.1 Million USD | 32.32% |
| 2023 Q2 | 9.9 Million USD | -34.87% |
| 2023 Q1 | 15.2 Million USD | -62.28% |
| 2023 FY | - USD | -19.85% |
| 2023 Q4 | 33.7 Million USD | 157.25% |
| 2022 FY | - USD | 159.28% |
| 2022 Q4 | 40.3 Million USD | 31.7% |
| 2022 Q3 | 30.6 Million USD | -0.65% |
| 2022 Q2 | 30.8 Million USD | 51.72% |
| 2022 Q1 | 20.3 Million USD | -41.16% |
| 2021 Q2 | 2.2 Million USD | 181.48% |
| 2021 Q4 | 34.5 Million USD | 157.46% |
| 2021 FY | - USD | 2470.0% |
| 2021 Q3 | 13.4 Million USD | 509.09% |
| 2021 Q1 | -2.7 Million USD | 92.04% |
| 2020 Q2 | 9.2 Million USD | -22.69% |
| 2020 Q1 | 11.9 Million USD | 30.77% |
| 2020 Q3 | 10.8 Million USD | 17.39% |
| 2020 FY | - USD | 83.47% |
| 2020 Q4 | -33.9 Million USD | -413.89% |
| 2019 Q4 | 9.1 Million USD | 212.35% |
| 2019 Q2 | 700 Thousand USD | 105.07% |
| 2019 Q3 | -8.1 Million USD | -1257.14% |
| 2019 Q1 | -13.8 Million USD | -545.16% |
| 2019 FY | - USD | -128.95% |
| 2018 FY | - USD | 121.16% |
| 2018 Q4 | 3.1 Million USD | -82.87% |
| 2018 Q3 | 18.1 Million USD | -3.72% |
| 2018 Q2 | 18.8 Million USD | 944.44% |
| 2018 Q1 | 1.8 Million USD | 101.56% |
| 2017 Q3 | 45.6 Million USD | -0.65% |
| 2017 FY | - USD | -87.66% |
| 2017 Q4 | -115.5 Million USD | -353.29% |
| 2017 Q2 | 45.9 Million USD | 6.99% |
| 2017 Q1 | 42.9 Million USD | 31.19% |
| 2016 Q3 | 37.7 Million USD | 11.21% |
| 2016 FY | - USD | -5.43% |
| 2016 Q4 | 32.7 Million USD | -13.26% |
| 2016 Q2 | 33.9 Million USD | -30.67% |
| 2016 Q1 | 48.9 Million USD | 36.21% |
| 2015 FY | - USD | -11.28% |
| 2015 Q4 | 35.9 Million USD | 17.32% |
| 2015 Q3 | 30.6 Million USD | -19.69% |
| 2015 Q2 | 38.1 Million USD | -33.62% |
| 2015 Q1 | 57.4 Million USD | 20.08% |
| 2014 Q1 | 80 Million USD | 6.67% |
| 2014 FY | - USD | -38.54% |
| 2014 Q2 | 13.9 Million USD | -82.63% |
| 2014 Q4 | 47.8 Million USD | 16.87% |
| 2014 Q3 | 40.9 Million USD | 194.24% |
| 2013 Q2 | 74.6 Million USD | 24.96% |
| 2013 Q4 | 75 Million USD | -14.58% |
| 2013 Q1 | 59.7 Million USD | 0.0% |
| 2013 FY | - USD | 3.09% |
| 2013 Q3 | 87.8 Million USD | 17.69% |
| 2012 FY | - USD | 8.39% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 99.492% |
| Allurion Technologies Inc. | -69.03 Million USD | 177.067% |
| Artivion, Inc. | 38.14 Million USD | -39.479% |
| Butterfly Network, Inc. | -124.84 Million USD | 142.613% |
| Butterfly Network, Inc. | -124.84 Million USD | 142.613% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 108.746% |
| Boston Scientific Corporation | 3.45 Billion USD | 98.459% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | 458.539% |
| CONMED Corporation | 182.18 Million USD | 70.799% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 96.99% |
| Paragon 28, Inc. | -36.61 Million USD | 245.3% |
| Glaukos Corporation | -82.11 Million USD | 164.786% |
| Globus Medical, Inc. | 418.23 Million USD | 87.28% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | 411.841% |
| Integer Holdings Corporation | 282.05 Million USD | 81.139% |
| Medtronic plc | 9.05 Billion USD | 99.413% |
| Nevro Corp. | -78.31 Million USD | 167.935% |
| Owlet, Inc. | -27.48 Million USD | 293.532% |
| Penumbra, Inc. | 111.99 Million USD | 52.498% |
| Vicarious Surgical Inc. | -69.19 Million USD | 176.888% |
| Smith & Nephew plc | 979 Million USD | 94.566% |
| Sonendo, Inc. | -54.76 Million USD | 197.137% |
| STERIS plc | 1.41 Billion USD | 96.233% |
| Stryker Corporation | 5.16 Billion USD | 98.969% |
| Vapotherm, Inc. | -34.35 Million USD | 254.845% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 97.828% |